4
Changes in Ownership
Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-21-054542
EVP and Chief Medical Officer sold 5,000 shares at an average $100.11 ($500,525)
- EVP and Chief Medical Officer acquired 5,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Bedrosian Camille L · EVP and Chief Medical Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-09-01 | Exercise or conversion : show line 1 in the form | +2,500 | $55.00 | $137,500 | 41,275 | D |
| 2021-09-01 | Sale : show line 2 in the form | −2,500 | $100.03 | $250,075 | 38,775 | D |
| 2021-09-02 | Exercise or conversion : show line 3 in the form | +2,500 | $55.00 | $137,500 | 41,275 | D |
| 2021-09-02 | Sale : show line 4 in the form | −2,500 | $100.18 | $250,450 | 38,775 | D |
| Open-market sales · 5,000 sh · avg $100.11 · $500,525 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2021-09-01 | Exercise or conversion : show line 5 in the form Stock Option (Right to Buy) | −2,500 | 55,500 | D |
| 2021-09-02 | Exercise or conversion : show line 6 in the form Stock Option (Right to Buy) | −2,500 | 53,000 | D |
Loading xslF345X03/doc4.xml…